How do chemotherapeutic agents damage the ovary?

Human Reproduction Update

Volumn 18, Issue 5, 2012, Pages 525-535

  Morgan, S ^a   Anderson, R A ^b   Gourley, C ^a   Wallace, W H ^c   Spears, N ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

Cancer; Chemotherapy; Female infertility; Follicle development; Ovary

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; BLEOMYCIN; BUSULFAN; CARMUSTINE; CISPLATIN; CISPLATIN DERIVATIVE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GONADORELIN AGONIST; HYDROXYUREA; IFOSFAMIDE; IMATINIB; IRINOTECAN; MELPHALAN; MERCAPTOPURINE; MESNA; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PREDNISONE; PROCARBAZINE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE;

APOPTOSIS; CANCER CHEMOTHERAPY; CELL DAMAGE; CELL DEATH; DNA DAMAGE; DRUG MEGADOSE; GERM CELL; HUMAN; NEOPLASM; NONHUMAN; OOCYTE; OVARY FOLLICLE; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SOMATIC CELL;

ANTINEOPLASTIC AGENTS; FEMALE; FERTILITY PRESERVATION; GONADOTROPIN-RELEASING HORMONE; HUMANS; OOCYTES; OVARIAN FOLLICLE; OVARY; PREGNANCY; PRIMARY OVARIAN INSUFFICIENCY; PROSPECTIVE STUDIES;

EID: 84865094333     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dms022     Document Type: Review

References (89)

1. Abir R, Ben-Haroush A, Felz C, Okon E, Raanani H, Orvieto R, Nitke S, Fisch B. Selection of patients before and after anticancer treatment for ovarian cryopreservation. Hum Reprod 2008;23:869-877.
2. Adriaens I, Smitz J, Jacquet P. The current knowledge on radiosensitivity of ovarian follicle development stages. Hum Reprod Update 2009;15:359-377.
3. Anders C, Marcom PK, Peterson B, Gu L, Unruhe S, Welch R, Lyons P, Behera M, Copland S, Kinnick G et al. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest 2008;26:286-295.
4. Anderson RA, Cameron DA. Pretreament serum Anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab 2011;96:1336-1343.
5. Anderson RA, Wallace WHB. Fertility preservation in girls and young women. Clin Endocrinol 2011;75:409-419.
6. Anderson RA, Themmen APN, Al-Qahtani A, Groome NP, Cameron DA. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 2006;21:2583-2592.
7. Ataya K, Tadros M, Ramahi A. Gonadotrophin-releasing hormone agonist inhibits physiologic ovarian folliclualr loss in rats. Acta Endocrinol 1989;121:55-60.
8. Bar-Joseph H, Ben-Aharon I, Rizel S, Stemmer SM, Tzabari M, Shalgi R. Doxorubicininduced apoptosis in germinal vesicle (GV) oocytes. Reprod Toxicol 2010; 30:566-572.
9. Beck-Fruchter R, Weiss A, Shalev E. GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data. Hum Reprod Update 2008;14:553-561.
10. Ben-Aharon I, Bar-Joseph H, Tzarfaty G, Kuchinsky L, Rizel S, Stemmer SM, Shalgi R. Doxorubicin-induced ovarian toxicity. Reprod Biol Endocrinol 2010; doi: 10.1186/ 1477-7827-8-20.
11. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996; 14:1718-1729.
12. Blumenfeld Z, von Wolff M. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum Reprod Update 2008; 14:543-552.
13. Brougham MFH, Crofton PM, Johnson EJ, Evans N, Anderson RA, Wallace WHB. Anti-Müllerian hormone is a marker of gonadotoxicity in pre- and post pubertal girls treated for cancer: a prospective study. J Clin Endocrinol Metab, in press.
14. de Bruin JP, Dorland M, Spek ER, Posthuma G, van Haaften M, Looman CWN, Te Velde ER. Ultrastructure of the resting ovarian follicle pool in healthy young women. Biol Reprod 2002;66:1151-1160.
15. Bruning P, Pit M, de Jong-Bakker M, van den Ende A, Hart A, van Enk A. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 1990;61:308-310.
16. Byrne J, Fears TR, Gail MH, Pee D, Connelly RR, Austin DF, Holmes GF, Holmes FF, Latourette HB, Meigs JW et al. Early menopause in long term survivors of cancer during adolescence. Am J Obstet Gynecol 1992;166:788-793.
17. Carter J, Rowland K, Chi D, Brown C, Abu-Rustum N, Castiel M, Barakat R. Gynecologic cancer treatment and the impact of cancer related infertility. Gynecol Oncol 2005;97:90-95.
18. Chiarelli AM, Marrett LD, Darlington G. Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964-1988 in Ontario, Canada. Am J Epidemiol 1999;150:245-254.
19. Choi JH, Gilks CB, Auersperg N, Leung PCK. Immunolocalization of gonadotropin-releasing Hormone (GnRH)-I, GnRH-II, and Type I GnRH receptor during follicular development in the human ovary. J Clin Endocrinol Metab 2006;91:4562-4570.
20. Choi JY, Jo MW, Lee EY, Yoon BK, Choi DS. The role of autophagy in follicular development and atresia in rat granulosa cells. Fertil Steril 2010;93:2532-2537.
21. Cooper AR, Baker VL, Sterling EW, Ryan ME, Woodruff TK, Nelson LM. The time is now for a new approach to primary ovarian insufficiency. Fertil Steril 2011; 95:1890-1897.
22. Decanter C, Morschhauser F, Pigny P, Lefebvre C, Gallo C, Dewailly D. Anti-Müllerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results. Reprod Biomed Online 2010;20:280-285.
23. Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, Giordano M, Garrone O, Pronzato P, Bighin C. Effect of the gonadotrophin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer. JAMA 2011;306:269-276.
24. Desmeules P, Devine PJ. characterizing the ovotoxicity of cyclophosphamide metabolites on cultured mouse ovaries. Toxicol Sci 2006;90:500-509.
25. Donnez J, Dolmans MM. Preservation of fertility in females with haemotological malignancy. Br J Haematol 2011;154:175-184.
26. Downs SM, Utecht AM. Metabolism of radiolabeled glucose by mouse oocytes and oocyte-cumulus cell complexes. Biol Reprod 1999;60:1446-1452.
27. Durlinger ALL, Kramer P, Karels B, De Jong FH, Uilenbroek JTJ, Grootegoed JA, Themmen APN. Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary. Endocrinology 1999;140:5789-5796.
28. Durlinger ALL, Kramer P, Karels B, Grootegoed JA, Uilenbroek JTJ, Themmen APN. Apoptotic and proliferative changes during induced atresia of pre-ovulatory follicles in the rat. Hum Reprod 2000;15:2504-2511.
29. Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, Fischer D, Sommer HL, Conrad B, Ortmann O. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 2011;29:2334-2341.
30. Gonfloni S. DNA damage stress response in germ cells: role of c-Abl and clinical implications. Oncogene 2010;29:6193-6202.
31. Gonfloni S, Tella LD, Caldarola S, Cannata SM, Klinger FG, Bartolomeo CD, Mattei M, Candi E, Felici MD, Melino G et al. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy induced death. Nat Med 2009;15:1179-1185.
32. Goswami D, Conway GS. Premature ovarian failure. Hum Reprod Update 2005; 11:391-410.
33. Hancke K, Strauch O, Kissel C, Gö bel H, Schäfer W, Denschlag D. Sphingosine 1-phosphate protects ovaries from chemotherapy-induced damage. Fertil Steril 2007;87:172-177.
34. Imai A, Sugiyama M, Furui T, Tamaya T, Ohno T. Direct protection by a gonadotropin-releasing hormone analog from doxorubicin-induced granulosa cell damage. Gynecol Obstet Invest 2007;63:102-106.
35. Jeanes H, Newby D, Gray GA. Cardiovascular risk in women: the impact of hormone replacement therapy and prospects for new therapeutic approaches. Expert Opin Pharmacother 2007;8:279-288.
36. Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature 2004;428:145-150.
37. Jurisicova A, Lee HJ, D'Estaing SG, Tilly J, Perez GI. Molecular requirements for doxorubicin-mediated death in murine oocytes. Cell Death Differ 2006; 13:1466-1474.
38. Kelsey TW, Anderson RA, Wright P, Nelson SM, Wallace WH. Data-driven assessment of the human ovarian reserve. Mol Hum Reprod 2012;18:79-87.
39. Kim JM, Yoon YD, Tsang BK. Involvement of the Fas/Fas ligand system in p53-mediated granulosa cell apoptosis during follicular development and atresia. Endocrinology 1999;140:2307-2317.
40. Kitajima Y, Endo T, Nagasawa K, Manase K, Honnma H, Baba T, Hayashi T, Chiba H, Sawada N, Saito T. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5. Endocrinology 2006;147:694-699.
41. La Marca A, Broekmans FJ, Volpe A, Fauser BC, Macklon NS. Anti-Müllerian hormone (AMH): what do we still need to know? Hum Reprod 2009; 24:2264-2275.
42. Letourneau JM, Ebbel EE, Katz PP, Oktay KH, McCulloch CE, Ai WZ, Chien AJ, Melisko ME, Cedars MI, Rosen MP. Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer. Cancer 2012a;118:1933-1939.
43. Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, Melisko ME, Cedars MI, Rosen MP. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer 2012b; 118:1710-1717.
44. Lower EE, Blau R, Gazder P, Tummala R. The risk of premature menopause induced by chemotherapy for early breast cancer. J Womens Health Genet Based Med 1999;8:949-954.
45. Mandic A, Hansson J, Linder S, Shoshan MC. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 2003; 278:9100-9106.
46. Marcello MF, Nuciforo G, Romeo R, Dino GD, Russo I, Russo A, Palumbo G, Schiliro' G. Structural and ultrastructural study of the ovary in childhood leukemia after successful treatment. Cancer 1990;66:2099-2104.
47. Matzuk MM, Burns KH, Viveiros MM, Eppig JJ. Intercellular communication in the mammalian ovary: oocytes carry the conversation. Science 2002;296:2178-2180.
48. Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol 2000;169:123-131.
49. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 2001;7:535-543.
50. Meirow D, Lewis H, Nugent D, Epstein M. Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. Hum Reprod 1999;14:1903-1907.
51. Meirow D, Dor J, Kaufman B, Shrim A, Rabinovici J, Schiff E, Raanani H, Levron J, Fridman E. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod 2007;22:1626-1633.
52. Meirow D, Biedermann H, Anderson RA, Wallace WH. Toxicity of chemotherapy and radiation on female reproduction. Clinical Obst and Gynaecol 2010; 53:727-739.
53. Morita Y, Tilly JL. Sphingolipid regulation of female gonadal cell apoptosis. Ann N Y Acad Sci 2000;905:209-220.
54. Morita Y, Perez GI, Paris F, Miranda SR, Ehleiter D, Haimovitz-Friedman A, Fuks Z, Xie Z, Reed JC, Schuchman EH et al. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med 2000;6:1109-1114.
55. Nelson SM, Anderson RA, Broekmans FJ, Raine-Fenning NJ, Fleming R, La Marca A. Anti-Müllerian hormone: clairvoyance or crystal clear? Hum Reprod 2012; 27:631-636.
56. Oktem O, Oktay K. A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Res 2007a; 67:10159-10162.
57. Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 2007b;110:2222-2229.
58. ONS. Cancer survival in England: one-year and five-year survival for 21 common cancers, by sex and age. Office for National Statistics, 2010.
59. Paris F, Perez GI, Fuks Z, Haimovitz-Friedman A, Nguyen H, Bose M, Ilagen A, Hunt PA, Morgan WF, Tilly JL et al. Sphinogosine 1-phosphate preserves fertility in irradiated female mice without propagating genomic damage in offspring. Nat Med 2002;8:901-902.
60. Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winder E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: Long-term results from International Breast Cancer Study Group Trials V and VI. Eu J Cancer 2007;43: 1646-1653.
61. Perez GI, Knudson CM, Leykin L, Korsmeyer SJ, Tilly JL. Apoptosis-associated signalling pathways are required for chemotherapy-mediated female germ cell destruction. Nat Med 1997;3:1228-1232.
62. Petrek JA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE, Sukumvanich P. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment. A prospective study. J Clin Oncol 2006; 24:1045-1051.
63. Petrillo SK, Desmeules P, Truong TQ, Devine PJ. Detection of DNA damage in oocytes of small ovarian follicles following phosphoramide mustard exposures of cultured rodent ovaries in vitro. Toxicol Appl Pharmacol 2011; 253:94-102.
64. Pointon AV, Walker TM, Phillips KM, Luo J, Riley J, Zhang SD, Parry JD, Lyon JJ, Marczylo EL, Gant TW. Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation. PLoS ONE 2010;5:e12733.
65. Raz A, Fisch B, Okon E, Feldberg D, Nitke S, Raanani H, Abir R. Possible direct cytotoxicity effects of cyclophosphamide on cultured human follicles: an electron microscopy study. J Assist Reprod Genet 2002;19:500-506.
66. Rosendahl M, Andersen CY, la Cour Freiesleben N, Juul A, Lossl K, Andersen AN. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age. Fertil Steril 2010;94:156-166.
67. Shakir DK, Rasul KI. Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management. J Clin Med Res 2009;1:8-12.
68. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-7279.
69. Sklar C. Maintenance of ovarian function and risk of premature menopause related to cancer treatment. J Natl Cancer Inst Monogr 2005;34:25-27.
70. Sklar CA, Mertens AC, Mitby P, Whitton J, Stovall M, Kasper C, Mulder J, Green D, Nicholson HS, Yasui Y et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 2006;98:890-896.
71. Smith ML, Suresh Kumar MA. The 'two faces' of tumour supressor p53-revisited. Mol Cell Pharmacol 2010;2:117-119.
72. Soleimani R, Heytens E, Darzynkiewicz Z, Oktay K. Mechanisms of chemotherapy-induced human ovarian aging: double strand DNA breaks and microvascular compromise. AGING 2011;3:782-793.
73. Stearns V, Schneider B, Henry NL, Hayes DF, Flockhart DA. Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. Nat Rev Cancer 2006;6:886-893.
74. Suh EK, Yang A, Kettenbach A, Bamberger C, Michaelis AH, Zhu Z, Elvin JA, Bronson RT, Crum CP, McKeon F. p63 protects the female germ line during meiotic arrest. Nature 2006;444:624-628.
75. Takeba Y, Sekine S, Kumai T, Matsumoto N, Nakaya S, Tsuzuki Y, Yanagida Y, Nakano H, Asakura T, Ohtsubo T et al. Irinotecan-induced apoptosis is inhibited by increased p-glycoprotein expression and decreased p53 in human heptocellular carcinoma cells. Biol Pharm Bull 2007;30:1400-1406.
76. Tan X, Wang DB, Wei H, Zhu R, Zhu SS, Jiang H, Yang ZJ. Doxorubicin induces apoptosis in H9c2 cardiomyocytes: role of overexpressed eukaryotic translation initiation factor 5A. Biol Pharm Bull 2010;10:1666-1672.
77. Tanaka T, Halicka HD, Traganos F, Seiter K, Darzynkiewicz Z. Induction of ATM Activation, Histone H2AX Phosphorylation and Apoptosis by Etoposide. Cell Cycle 2007;6:371-376.
78. Thomson AB, Critchley HOD, Kelnar CJH, Wallace WHB. Late reproductive sequelae following treatment of childhood cancer and options for fertility preservation. Best Pract Res Clin Endocrinol Metab 2002;16:311-334.
79. Tilly JL. Apoptosis and ovarian function. Rev Reprod 1996;1:162-172.
80. Tingen CM, Brostol-Gould SK, Kiesewetter SE, Wellington JT, Shea L, Woodruff TK. Prepubertal primordial follicle loss in mice is not due to classical apoptotic pathways. Biol Reprod 2009;81:16-25.
81. Utsunomiya T, Tanaka T, Utsunomiya H, Umesaki N. A novel molecular mechanism for anticancer drug-induced ovarian failure: irinotecan HCl, an anticancer topoisomerase I inhibitor, induces specific FasL expression in granulosa cells of large ovarian follicles to enhance follicular apotosis. Intl J Oncol 2008; 32:991-1000.
82. Wallace WHB, Kelsey TW. Human ovarian reserve from conception to the menopause. PLoS ONE 2010;5:e8772.
83. Waxman JH, Ahmed R, Smith D, Wrigley PF, Gregory W, Shalet S, Crowther D, Rees LH, Besser GM, Malpas JS et al. Failure to preserve fertility in patients with Hodgkins disease. Cancer Chemother Pharmacol 1987;19:159-162.
84. Weenen C, Laven JSE, von Bergh ARM, Cranfield M, Groome NP, Visser JA, Kramer P, Fauser BCJM, Themmen APN. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for intial and cyclic follicle recruitment. Mol Hum Reprod 2004;10:77-83.
85. Welt C. Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin Endocrinol 2008;68:499-509.
86. Yucebilgin MS, Terek MC, Ozsaran A, Akercan F, Zekioglu O, Isik E, Erhan Y. Effect of chemotherapy on primordial follicular reserve of rat: An animal model of premature ovarian failure and infertility. Aust N Z J Obstet Gynaecol 2004;44: 6-9.
87. Zamah AM, Maura MJ, Druker BJ, Oktay K, Egorin MJ, Cedards MI, Rosen MP. Will imatinib compromise reproductive capacity? Oncologist 2011;16:1422-1427.
88. Zelinski MB, Murphy MB, Lawson BS, Juriscova A, Pau KYF, Toscano NP, Jacob DS, Fanton JK, Casper RF, Dertinger SD et al. In vivo delivery of FTY720 prevents radiation-induced ovarian failure and infertility in adult female nonhuman primates. Fertil Steril 2011;95:1440-1445.
89. Zhao XI, Huang YH, Yu YC, Xin XY. GnRH antagonist cetrorelix inhibits mitochondria-dependant apoptosis triggered by chemotherapy in granulosa cells of rats. Gynecol Oncol 2010;118:69-75.